colleagues' concern that there may be bias toward patients with more progressive disease in the control group compared with the treated group appears unlikely. The 20% of patients in the control group who had discontinued immunomodulatory or immunosuppressive treatment in the first 3 to 6 weeks bec
Glutamic acid decarboxylase antibodies in Satoyoshi syndrome
β Scribed by Gea Drost; Aad Verrips; Herbert Hooijkaas; Machiel Zwarts
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 193 KB
- Volume
- 55
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Glutamic acid decarboxylase (GAD) is an enzyme that catalyzes the conversion of glutamate to β₯-aminobutyric acid (GABA). Anti-GAD antibody (GAD-Ab) is considered to be a marker for stiff person syndrome (SPS), 1 insulin-dependent diabetes mellitus (IDDM), and polyendocrine autoimmune syndrome. 2 Add
Since the decarboxylation of glutamic acid into y-aminobutyric acid (GABA) involves a release of COz, we easily understand the widespread use of manometric methods for the determination of glutamic acid decarboxylase activity (GADA) (l-13,29,30). Other investigators (14-16) have chosen to measure G